Developer docs
API playgroundTry for free, no card

Search company profiles

Valencia Technologies

Full company profile

uuid0000pzd

Namestring
Valencia Technologies
Legal namestring
Valencia Technologies Corporation
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Valencia Technologies is a neuromodulation medical device company that developed and commercialized the eCoin System, the first and only FDA PMA-approved fully integrated, subcutaneously implantable tibial nerve stimulator for the treatment of urgency urinary incontinence (UUI), the most bothersome symptom of overactive bladder (OAB). Founded in 2011 and headquartered in Valencia, California, the company addresses a large underserved patient population—over 40 million women in the US suffer from UUI. The eCoin device is a coin-sized, leadless neurostimulator containing a primary-cell battery (1–8 year service life depending on amplitude) that is implanted subcutaneously near the ankle during a minimally invasive outpatient procedure of approximately 20 minutes under local anesthetic; it automatically delivers intermittent stimulation to the tibial nerve twice weekly via a forgiving dome-shaped stimulation field, with no lead wires, external remotes, recharging, or patient device management required. In the pivotal trial, 75% of patients (per protocol) achieved at least a 50% reduction in UUI episodes at one year, with an 89% recommendation rate and a 2.3% infection rate.

The company generates revenue through unit hardware sales of the eCoin device to hospitals, ambulatory surgery centers, and physician practices, reimbursed under Category III CPT code 0816T (APC 5464) at approximately $21,063 in the Medicare Hospital Outpatient setting and $19,464 in the ASC setting for CY2025. Distribution is via a direct enterprise sales force targeting urologists, urogynecologists, and female pelvic medicine specialists who must complete the eCoin Physician Qualification training program before implantation; patient access is supported by a partnership with PRIA Healthcare for prior-authorization and payer education. By May 2024, more than 1,100 patients in the US had been treated with eCoin. In February 2025, Valencia received up to $35 million in strategic investment from Brooks Advisory Group and appointed Jim Surek as CEO; in January 2026, Boston Scientific announced an agreement to acquire the company, completing the acquisition in April 2026 and integrating eCoin into its urology and pelvic health portfolio.

Short descriptiontext

Valencia Technologies is a neuromodulation medical device company that developed the eCoin System, the first FDA PMA-approved leadless implantable tibial nerve stimulator for urgency urinary incontinence. The company was acquired by Boston Scientific in April 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersValencia, United States
HQ citystring
Valencia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
implantable neurostimulators, tibial nerve stimulation, urinary incontinence treatment, neuromodulation medical devices, bladder dysfunction therapy
Industry1 code
PRIMARYHLAHALAH
Continence Care Products (Adult Incontinence Pads/Briefs, Underpads, External Collectors)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Implantable Neuromodulation Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1eCoin Device Sales
TypeHardware Sales
Description

Valencia Technologies generates revenue from the sale of its eCoin implantable tibial nerve stimulation device to hospitals, ambulatory surgery centers, and physician practices for the treatment of urgency urinary incontinence.

news.pedaily.cn
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Medicare Hospital Outpatient (HOPPS) reimbursement for eCoin procedure
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CMS CY2025 proposed unadjusted national average payment rate of US$21,063 for CPT code 0816T under APC 5464 (Hospital Outpatient)

valenciatechnologies.com
2Medicare ASC (Ambulatory Surgical Center) reimbursement for eCoin procedure
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CMS CY2025 proposed national unadjusted ASC payment rate of $19,464 for CPT code 0816T, representing a 38% increase over the CY2024 rate of $14,122

valenciatechnologies.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1eCoin
Description

The eCoin system is a coin-sized implantable tibial nerve stimulator for treating urge urinary incontinence (UUI). It is the first and only FDA-approved fully implantable device for this indication.

valenciatechnologies.com
Core offering1 text field

Valencia Technologies designs, manufactures, and sells the eCoin System, a coin-sized, leadless, FDA PMA-approved implantable tibial neurostimulator that automatically delivers intermittent stimulation to the tibial nerve for the treatment of urgency urinary incontinence (UUI) secondary to overactive bladder. The device is implanted subcutaneously near the ankle during a ~20-minute outpatient procedure under local anesthetic and is sold to urologists, urogynecologists, hospitals, and ambulatory surgery centers in the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 75% responder rate (at least 50% reduction in UUI episodes at one year, per protocol population)
+6 more records
Product overview1 text field

Valencia Technologies is a neuromodulation company with a single core product offering: the eCoin System. The eCoin System is a pioneering, leadless implantable tibial nerve stimulator (ITNS) for treating urgency urinary incontinence (UUI), the primary symptom of overactive bladder. The company operates as a medical device manufacturer and has been acquired by Boston Scientific (April 2026). The eCoin device is the first and only FDA PMA-approved fully integrated, subcutaneously implantable medical device designed to automatically stimulate the tibial nerve.

Product and service1 record
1eCoin System
CategoryImplantable Neuromodulation Devices (Tibial Nerve Stimulation)
Description

Coin-sized, leadless implantable neurostimulator that automatically delivers intermittent stimulation to the tibial nerve twice weekly for the treatment of urgency urinary incontinence (UUI) secondary to overactive bladder. Implanted subcutaneously near the ankle during a ~20-minute outpatient procedure under local anesthetic. FDA PMA-approved and sold to urologists, urogynecologists, hospitals, and ambulatory surgery centers in the U.S.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2022-05-10
Description

Valencia retained PRIA Healthcare to assist in patient access for the FDA-approved eCoin device. PRIA develops patient-centric prior authorization and appeals programs, leverages clinical evidence to inform payors, and educates insurance companies on the clinically supported benefits of eCoin. PRIA has 10 years of experience assisting MedTech companies with patient access to new medical devices.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Medtronic's InterStim sacral neuromodulation system is the dominant FDA-approved implantable therapy for refractory urge urinary incontinence, making it the closest direct competitor to Valencia's eCoin ITNS in target indication, customer (urologists), and treatment modality (implantable neurostimulation).

TypeDirect peer
Description

Axonics offers the r-SNM sacral neuromodulation system for OAB and urge incontinence, directly competing with eCoin for the same urology/urogynecology channel and FDA-approved implantable neurostimulation category.

3Abbott Laboratories
TypeBroad incumbent
Description

Abbott's neuromodulation division (inherited from St. Jude Medical) sells Proclaim DRG and Proclaim Elite neurostimulators and is a broad incumbent in implantable neurostimulation across multiple indications, providing competitive overlap in physician mindshare and hospital contracting.

TypeBroad incumbent
Description

Boston Scientific is Valencia's acquirer (April 2026) and operates a broader neuromodulation and pelvic-health portfolio including spinal cord stimulators, urogynecology slings, and the Greenlight laser system, into which eCoin is now integrated.

TypeBroad incumbent
Description

Laborie, which acquired Cogentix/Endo International's urology business, is a broader urology device incumbent offering diagnostic and therapeutic OAB products, providing a comparable specialty channel and customer base for incontinence therapies.

TypeEmerging player
Description

Inspire's hypoglossal nerve stimulation implant for obstructive sleep apnea shares the same business model as Valencia: a single FDA-approved implantable neurostimulator targeting a specific specialty indication, with analogous reimbursement, sales-force build-out, and adoption curve.

TypeEmerging player
Description

Nuvectra developed Algovita and other implantable neurostimulators for pain and urology indications, providing a peer in the specialty implantable neuromodulation category with similar stage and commercialization challenges.

TypeEmerging player
Description

Cala Health develops wearable transcutaneous neurostimulation devices for chronic conditions (essential tremor, etc.), offering a comparable neuromodulation platform targeting a defined specialty channel but with a non-invasive delivery model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Valencia Technologies

Implantable Neuromodulation Devicesvalenciatechnologies.com

Valencia Technologies is a neuromodulation medical device company that developed the eCoin System, the first FDA PMA-approved leadless implantable tibial nerve stimulator for urgency urinary incontinence. The company was acquired by Boston Scientific in April 2026.

What Valencia Technologies does

Valencia Technologies is a neuromodulation medical device company that developed and commercialized the eCoin System, the first and only FDA PMA-approved fully integrated, subcutaneously implantable tibial nerve stimulator for the treatment of urgency urinary incontinence (UUI), the most bothersome symptom of overactive bladder (OAB). Founded in 2011 and headquartered in Valencia, California, the company addresses a large underserved patient population—over 40 million women in the US suffer from UUI. The eCoin device is a coin-sized, leadless neurostimulator containing a primary-cell battery (1–8 year service life depending on amplitude) that is implanted subcutaneously near the ankle during a minimally invasive outpatient procedure of approximately 20 minutes under local anesthetic; it automatically delivers intermittent stimulation to the tibial nerve twice weekly via a forgiving dome-shaped stimulation field, with no lead wires, external remotes, recharging, or patient device management required. In the pivotal trial, 75% of patients (per protocol) achieved at least a 50% reduction in UUI episodes at one year, with an 89% recommendation rate and a 2.3% infection rate.

The company generates revenue through unit hardware sales of the eCoin device to hospitals, ambulatory surgery centers, and physician practices, reimbursed under Category III CPT code 0816T (APC 5464) at approximately $21,063 in the Medicare Hospital Outpatient setting and $19,464 in the ASC setting for CY2025. Distribution is via a direct enterprise sales force targeting urologists, urogynecologists, and female pelvic medicine specialists who must complete the eCoin Physician Qualification training program before implantation; patient access is supported by a partnership with PRIA Healthcare for prior-authorization and payer education. By May 2024, more than 1,100 patients in the US had been treated with eCoin. In February 2025, Valencia received up to $35 million in strategic investment from Brooks Advisory Group and appointed Jim Surek as CEO; in January 2026, Boston Scientific announced an agreement to acquire the company, completing the acquisition in April 2026 and integrating eCoin into its urology and pelvic health portfolio.

Valencia Technologies firmographics

Firmographics
Name
Valencia Technologies
Legal name
Valencia Technologies Corporation
Website
https://valenciatechnologies.com
Company type
Private
Founded year
2011
Operating status
Acquired
Headcount range
51–100 employees
Short description
Valencia Technologies is a neuromodulation medical device company that developed the eCoin System, the first FDA PMA-approved leadless implantable tibial nerve stimulator for urgency urinary incontinence. The company was acquired by Boston Scientific in April 2026.
Ownership category
akta.pro rank

Valencia Technologies industry classification

Industry
Product category
Implantable Neuromodulation Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHALAH
Continence Care Products (Adult Incontinence Pads/Briefs, Underpads, External Collectors)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Implantable neurostimulators
  • Tibial nerve stimulation
  • Urinary incontinence treatment
  • Neuromodulation medical devices
  • Bladder dysfunction therapy

Where Valencia Technologies is headquartered

Location

Headquarters

HQ city
Valencia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Valencia Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. eCoin Device Sales: Valencia Technologies generates revenue from the sale of its eCoin implantable tibial nerve stimulation device to hospitals, ambulatory surgery centers, and physician practices for the treatment of urgency urinary incontinence.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goMedicare Hospital Outpatient (HOPPS) reimbursement for eCoin procedure
Unit PricingPay-as-you-goMedicare ASC (Ambulatory Surgical Center) reimbursement for eCoin procedure

Go-to-market motion2 records

Distribution channels1 record

Marketing channels10 records

Valencia Technologies product offering

Product offering

Core offering

Valencia Technologies designs, manufactures, and sells the eCoin System, a coin-sized, leadless, FDA PMA-approved implantable tibial neurostimulator that automatically delivers intermittent stimulation to the tibial nerve for the treatment of urgency urinary incontinence (UUI) secondary to overactive bladder. The device is implanted subcutaneously near the ankle during a ~20-minute outpatient procedure under local anesthetic and is sold to urologists, urogynecologists, hospitals, and ambulatory surgery centers in the United States.

Product overview

Valencia Technologies is a neuromodulation company with a single core product offering: the eCoin System. The eCoin System is a pioneering, leadless implantable tibial nerve stimulator (ITNS) for treating urgency urinary incontinence (UUI), the primary symptom of overactive bladder. The company operates as a medical device manufacturer and has been acquired by Boston Scientific (April 2026). The eCoin device is the first and only FDA PMA-approved fully integrated, subcutaneously implantable medical device designed to automatically stimulate the tibial nerve.

Differentiator

Problem solved

Functional benefit

Brands

  • eCoin: The eCoin system is a coin-sized implantable tibial nerve stimulator for treating urge urinary incontinence (UUI). It is the first and only FDA-approved fully implantable device for this indication.

Products and services

  • eCoin System Coin-sized, leadless implantable neurostimulator that automatically delivers intermittent stimulation to the tibial nerve twice weekly for the treatment of urgency urinary incontinence (UUI) secondary to overactive bladder. Implanted subcutaneously near the ankle during a ~20-minute outpatient procedure under local anesthetic. FDA PMA-approved and sold to urologists, urogynecologists, hospitals, and ambulatory surgery centers in the U.S.

Quantifiable outcome

  • 75% responder rate (at least 50% reduction in UUI episodes at one year, per protocol population)
  • +6 more outcomes

Companies that use Valencia Technologies

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Valencia Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Valencia Technologies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • PRIA HealthcarecoreImplementation/ SI/ Consulting Partner · 10 May 2022Valencia retained PRIA Healthcare to assist in patient access for the FDA-approved eCoin device. PRIA develops patient-centric prior authorization and appeals programs, leverages clinical evidence to inform payors, and educates insurance companies on the clinically supported benefits of eCoin. PRIA has 10 years of experience assisting MedTech companies with patient access to new medical devices.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Valencia Technologies competitors and assessment

Company assessment

Direct peers

  • Medtronic plc: Medtronic's InterStim sacral neuromodulation system is the dominant FDA-approved implantable therapy for refractory urge urinary incontinence, making it the closest direct competitor to Valencia's eCoin ITNS in target indication, customer (urologists), and treatment modality (implantable neurostimulation).
  • Axonics, Inc. Axonics offers the r-SNM sacral neuromodulation system for OAB and urge incontinence, directly competing with eCoin for the same urology/urogynecology channel and FDA-approved implantable neurostimulation category.

Broad incumbents

  • Abbott Laboratories: Abbott's neuromodulation division (inherited from St. Jude Medical) sells Proclaim DRG and Proclaim Elite neurostimulators and is a broad incumbent in implantable neurostimulation across multiple indications, providing competitive overlap in physician mindshare and hospital contracting.
  • Boston Scientific Corporation: Boston Scientific is Valencia's acquirer (April 2026) and operates a broader neuromodulation and pelvic-health portfolio including spinal cord stimulators, urogynecology slings, and the Greenlight laser system, into which eCoin is now integrated.
  • Laborie Medical Technologies (Cogentix): Laborie, which acquired Cogentix/Endo International's urology business, is a broader urology device incumbent offering diagnostic and therapeutic OAB products, providing a comparable specialty channel and customer base for incontinence therapies.

Emerging players

  • Inspire Medical Systems: Inspire's hypoglossal nerve stimulation implant for obstructive sleep apnea shares the same business model as Valencia: a single FDA-approved implantable neurostimulator targeting a specific specialty indication, with analogous reimbursement, sales-force build-out, and adoption curve.
  • Nuvectra Corporation: Nuvectra developed Algovita and other implantable neurostimulators for pain and urology indications, providing a peer in the specialty implantable neuromodulation category with similar stage and commercialization challenges.
  • Cala Health: Cala Health develops wearable transcutaneous neurostimulation devices for chronic conditions (essential tremor, etc.), offering a comparable neuromodulation platform targeting a defined specialty channel but with a non-invasive delivery model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Valencia Technologies social profiles

Digital presence

Valencia Technologies compliance and trust

Trust signal

Compliance1 record

Valencia Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Valencia Technologies leadership team

Management profile

Number of profiles

Profiles11 records

Valencia Technologies funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Valencia Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valencia Technologies

What does Valencia Technologies do?

Valencia Technologies designs, manufactures, and sells the eCoin System, a coin-sized, leadless, FDA PMA-approved implantable tibial neurostimulator that automatically delivers intermittent stimulation to the tibial nerve for the treatment of urgency urinary incontinence (UUI) secondary to overactive bladder. The device is implanted subcutaneously near the ankle during a ~20-minute outpatient procedure under local anesthetic and is sold to urologists, urogynecologists, hospitals, and ambulatory surgery centers in the United States.

Is Valencia Technologies a public or private company?

Valencia Technologies is a private company. It is classified as corporate owned and is currently acquired.

When was Valencia Technologies founded?

Valencia Technologies was founded in 2011. It employs 51 to 100 people.

Where is Valencia Technologies based?

Valencia Technologies is headquartered in Valencia, United States, in the North America region.

How does Valencia Technologies make money?

One revenue line is on record: eCoin Device Sales.

Who are Valencia Technologies's main competitors?

Direct peers on record are Medtronic plc and Axonics, Inc.. Broad incumbents are Abbott Laboratories, Boston Scientific Corporation and Laborie Medical Technologies (Cogentix). Emerging players are Inspire Medical Systems, Nuvectra Corporation and Cala Health.

Does Valencia Technologies have an API?

No public API is recorded for Valencia Technologies.

What industry is Valencia Technologies in?

Valencia Technologies's product category is Implantable Neuromodulation Devices. Its primary akta.pro industry code is HLAHALAH, Continence Care Products (Adult Incontinence Pads/Briefs, Underpads, External Collectors). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comNeuromodulation Devices Industry Set to Strategic Investment by United States & JapanDataM Intelligence published its Neuromodulation Devices Market report, valued at US$111.56 billion in 2025 and projected to reach US$203.45 billion by 2033, growing at a 7.0% CAGR from 2026 to 2033. The report highlights strategic investments from the United States and Japan, FDA approvals for Saluda Medical's CAP24 paddle lead and Bioness Medical's PoNS system, and notable M&A activity including Medtronic's acquisition of SPR Therapeutics and Boston Scientific's acquisitions of Nalu Medical and Valencia Technologies. Key players including Medtronic, Boston Scientific, Abbott, Nevro Corp., and Inspire Medical Systems are driving growth through AI-enabled stimulation technologies, remote monitoring capabilities, and portfolio expansion across chronic pain, urology, and neurological applications.Grand View ResearchImplantable Tibial Neuromodulation Market Report 2026-2033The global implantable tibial neuromodulation market was valued at USD 51.5 million in 2025 and is projected to grow to USD 87.4 million by 2033, at a CAGR of 6.9%, driven by rising prevalence of overactive bladder and urinary incontinence alongside increasing demand for minimally invasive treatment options. North America held the largest regional market share at 36.1% in 2025, supported by advanced healthcare infrastructure and early adoption of innovative therapies. Key recent developments include Boston Scientific Corporation's January 2026 announcement to acquire Valencia Technologies, Medtronic's FDA approval for its Altaviva device in September 2025, and the first clinical implantation of the device in January 2026.Medical Device NetworkFDA clears Bright Uro’s abdominal sensor for evaluating bladder dysfunctionThe FDA cleared Bright Uro's abdominal sensor, adding multi-channel urodynamic and pressure studies to its Glean urodynamics system for bladder dysfunction. The clearance enables catheter-free ambulatory urodynamics for lower urinary tract dysfunction, with an estimated 80 million US patients affected.MassDeviceBoston Scientific completes Valencia Technologies acquisitionBoston Scientific has completed its acquisition of Valencia Technologies, a urinary incontinence treatment developer, expanding its pelvic health portfolio to include implantable tibial nerve stimulation (ITNS) therapy. Valencia's FDA-approved eCoin device, a coin-sized implant placed near the ankle, demonstrated a 68% patient response rate in clinical trials for treating urge urinary incontinence. This marks Boston Scientific's second acquisition completed in 2026, following its deal for Nalu Medical, as the company continues to build out its urology and pelvic health offerings.Mpo-mag2026 Medical Device Industry M&A Roundup (Updated 1/15)The article provides a roundup of mergers and acquisitions (M&A) in the medical device industry as of January 2026, highlighting recent transactions involving major companies such as Boston Scientific, Valencia Technologies, Haemonetics, and others. Key deals include Boston Scientific's acquisition of Penumbra for $14.5 billion and Valencia Technologies' implantable device, with several transactions being terminated due to regulatory or shareholder rejection.PR NewswireBoston Scientific Announces Agreement to Acquire Valencia Technologies CorporationBoston Scientific Corporation announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on treating bladder dysfunction. The acquisition will add the eCoin System, an FDA-approved implantable tibial nerve stimulation device for urge urinary incontinence, expanding Boston Scientific's urology and pelvic health portfolio. The transaction is expected to close in the first half of 2026 with immaterial impact on adjusted earnings per share in 2026, subject to customary closing conditions and undisclosed financial terms.FierceBiotechBoston Scientific snaps up Valencia Technologies to bolster urology offeringsBoston Scientific has acquired privately held medtech company Valencia Technologies for its eCoin System, an FDA-approved implantable tibial nerve stimulation device that treats urge urinary incontinence, a symptom of overactive bladder disorder. Financial terms of the deal were not disclosed. Analysts at Evercore ISI noted that these types of devices could potentially double the bladder stimulation market, as an alternative to Botox which requires repeated injections, and also referenced Medtronic's rival Altaviva device that received FDA approval in September.Mpo-magBoston Scientific to Buy Urinary Incontinence Treatment Maker Valencia TechnologiesBoston Scientific has begun a deal to acquire Valencia Technologies, a medical device company that developed the eCoin system, an FDA-approved implantable tibial nerve stimulation device for treating urinary urge incontinence. In clinical trials, 68% of patients responded with at least a 50% reduction in UUI episodes, and Boston Scientific expects to complete the acquisition in the first half of 2026. The company says the acquisition will expand its urology business into a high-growth adjacency and complement its existing pelvic health product line.FinSMEsValencia Technologies Receives Strategic Investment of up to $35M Appoints James D. Surek as CEOValencia Technologies announced a strategic investment of up to $35M and appointed James D. Surek as CEO. The funds will accelerate growth of its eCoin system, a subcutaneous implantable tibial nerve stimulator for urinary incontinence, which received FDA approval in 2022.